Duchenne News Tags: Italfarmaco

July 5, 2023
Italfarmaco announces that the FDA has completed filing review and accepted the company’s NDA for Givinostat.
June 27, 2022
On Saturday, June 25, 2022, Italfarmaco Group shared a press release regarding positive topline data from its completed Phase 3 EPIDYS trial with Givinostat.

Experience the magic of camp promise

Complete applications due April 3, 2023.